Management of Anticoagulation for Upper GI Endoscopy
Whether a patient needs to discontinue blood thinners before an upper GI scope depends entirely on whether the procedure is diagnostic only or involves high-risk interventions, and on the specific anticoagulant being used.
Risk Stratification Framework
The first critical step is determining your procedure risk:
Low-Risk Procedures (Can Continue Anticoagulation)
- Diagnostic upper endoscopy with mucosal biopsies is considered low-risk 1, 2
- These procedures have bleeding risk <1.5% 3
High-Risk Procedures (Require Anticoagulation Modification)
- Endoscopic mucosal resection (EMR)
- Endoscopic submucosal dissection (ESD)
- Variceal treatment
- Laser therapy or mucosal ablation
- Any therapeutic intervention with bleeding risk ≥1.5% 2, 3, 4
Specific Management by Anticoagulant Type
For Warfarin
Low-risk procedures (diagnostic EGD with biopsy):
- Continue warfarin without interruption 1
- Check INR within the week before the procedure
- Ensure INR is within therapeutic range (not exceeding it)
- If INR >5, defer the procedure and contact anticoagulation clinic 1
High-risk procedures:
- Stop warfarin 5 days before the procedure 1, 5
- Check INR prior to procedure to ensure <1.5 1
- Resume warfarin the evening of the procedure with usual maintenance dose 1
- Bridging with LMWH is only needed for patients at high thrombotic risk (not routine) 1, 5, 6
For Direct Oral Anticoagulants (DOACs)
Low-risk procedures:
- Simply omit the morning dose on the day of the procedure 1
- No other interruption needed
High-risk procedures:
- Stop DOACs 3 days (72 hours) before the procedure 1
- Exception: For dabigatran with CrCl 30-50 mL/min, stop 5 days before 1
- Resume DOACs 2-3 days after the procedure once hemostasis is confirmed 5, 6
- Do not bridge with heparin - DOACs have rapid onset of action (1-4 hours) 5, 6
For Antiplatelet Agents
Aspirin (single agent):
- Continue aspirin for all procedures including high-risk interventions 5, 6, 3
- Discontinuation causes approximately threefold increase in thrombotic complications 6
- Only stop for ultra-high risk procedures if explicitly requested by endoscopist 5
P2Y12 Inhibitors (clopidogrel, prasugrel, ticagrelor):
- Low-risk procedures: Continue without interruption 3
- High-risk procedures: Stop 5 days before the procedure 5, 6
- Resume once adequate hemostasis achieved 5
Dual Antiplatelet Therapy (DAPT):
- For high-risk procedures: Stop P2Y12 inhibitor 5 days before but continue aspirin 5
- Never stop both agents simultaneously 5
- In patients with recent coronary stents (<6-12 months), strongly consider postponing elective procedures 1, 6
Critical Thrombotic Risk Considerations
High thrombotic risk patients requiring special attention:
- Mechanical heart valves (especially mitral position)
- Atrial fibrillation with CHA₂DS₂-VASc score ≥5
- Recent stroke/TIA (<3 months)
- Recent venous thromboembolism (<3 months)
- Recent coronary stent placement (<6-12 months depending on stent type) 1, 6
For these patients undergoing high-risk procedures, bridging with LMWH may be appropriate when stopping warfarin 1, 5.
Common Pitfalls to Avoid
Do not routinely bridge DOACs with heparin - this increases bleeding risk without benefit given their rapid pharmacokinetics 5, 6
Do not stop aspirin perioperatively - the thrombotic risk far exceeds bleeding risk in most cases 5, 6
Do not use prophylactic heparin dosing for bridging - if bridging is needed, use therapeutic LMWH dosing 1
Do not assume all upper endoscopies are the same - a diagnostic EGD with biopsy is fundamentally different from EMR or ESD in bleeding risk 2, 3
For patients on temporary anticoagulation (recent DVT, recent stent), strongly consider postponing elective procedures until the high-risk period has passed 6, 7